These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23176620)

  • 21. [Treatment of pancreatic cancer. Actuality and perspective].
    Bittoni A; Andrikou K; Lanese A; Santoni M; Pellei C; Faloppi L; Del Prete M; Giampieri R; Cascinu S
    Recenti Prog Med; 2015 May; 106(5):208-16. PubMed ID: 25994537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomics and pharmacogenomics of pancreatic adenocarcinoma.
    Lowery MA; O'Reilly EM
    Pharmacogenomics J; 2012 Feb; 12(1):1-9. PubMed ID: 22186617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box".
    Tholey R; Sawicki JA; Brody JR
    Cancer J; 2012; 18(6):665-73. PubMed ID: 23187855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
    Weinberg BA; Yabar CS; Brody JR; Pishvaian MJ
    Oncology (Williston Park); 2015 Nov; 29(11):809-20, 886. PubMed ID: 26573060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
    Pishvaian MJ; Brody JR
    Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
    Mosquera C; Maglic D; Zervos EE
    Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular alterations contributing to pancreatic cancer chemoresistance.
    Rajabpour A; Rajaei F; Teimoori-Toolabi L
    Pancreatology; 2017; 17(2):310-320. PubMed ID: 28065383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nursing Implications of Chemotherapy Agents and Their Associated Side Effects in Patients With Pancreatic Cancer.
    Hronek JW; Reed M
    Clin J Oncol Nurs; 2015 Dec; 19(6):751-7. PubMed ID: 26583639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs in preclinical and early-stage clinical development for pancreatic cancer.
    Asuthkar S; Rao JS; Gondi CS
    Expert Opin Investig Drugs; 2012 Feb; 21(2):143-52. PubMed ID: 22217246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?
    Varadhachary GR; Wolff RA
    J Oncol Pract; 2016 Sep; 12(9):797-805. PubMed ID: 27621332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-gene signaling pathways in pancreatic cancer.
    Drakaki A; Iliopoulos D
    Biomed J; 2013; 36(5):200-8. PubMed ID: 24225187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
    Matera R; Saif MW
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.
    Dhayat S; Mardin WA; Mees ST; Haier J
    Int J Cancer; 2011 Sep; 129(5):1031-41. PubMed ID: 21413017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.
    Rahib L; Fleshman JM; Matrisian LM; Berlin JD
    JAMA Oncol; 2016 Sep; 2(9):1209-16. PubMed ID: 27270617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).
    Uccello M; Moschetta M; Mak G; Alam T; Henriquez CM; Arkenau HT
    Curr Oncol; 2018 Feb; 25(1):e90-e94. PubMed ID: 29507500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refinement of adjuvant therapy for pancreatic cancer.
    O'Reilly EM
    JAMA; 2010 Sep; 304(10):1124-5. PubMed ID: 20823441
    [No Abstract]   [Full Text] [Related]  

  • 37. Chemotherapy of pancreatic cancer.
    Smith FP; Schein PS
    Semin Oncol; 1979 Sep; 6(3):368-77. PubMed ID: 388637
    [No Abstract]   [Full Text] [Related]  

  • 38. Pancreatic Neoplasms and Autophagy.
    Barton LA; Ren J
    Curr Drug Targets; 2018; 19(9):1018-1023. PubMed ID: 27358060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].
    Löhr JM; Faissner R; Findeisen P; Neumaier M
    Internist (Berl); 2006 Jun; 47 Suppl 1():S40-8. PubMed ID: 16773365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adverse event and countermeasure with regard to FOLFIRINOX for pancreatic cancer].
    Koga F; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():597-603. PubMed ID: 25831830
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.